Literature DB >> 1970124

Biological properties of a CD4 immunoadhesin.

R A Byrn1, J Mordenti, C Lucas, D Smith, S A Marsters, J S Johnson, P Cossum, S M Chamow, F M Wurm, T Gregory, J E Groopman, D J Capon.   

Abstract

Molecular fusions of CD4, the receptor for human immunodeficiency virus (HIV), with immunoglobulin (termed CD4 immunoadhesins) possess both the gp120-binding and HIV-blocking properties of recombinant soluble CD4, and certain properties of IgG, notably long plasma half-life and Fc receptor binding. Here we show that a CD4 immunoadhesin can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) towards HIV-infected cells, although, unlike natural anti-gp120 antibodies, it does not allow ADCC towards uninfected CD4-expressing cells that have bound soluble gp120 to the CD4 on their surface. In addition, CD4 immunoadhesin, like natural IgG molecules, is efficiently transferred across the placenta of a primate. These observations have implications for the therapeutic application of CD4 immunoadhesins, particularly in the area of perinatal transmission of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970124     DOI: 10.1038/344667a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  54 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  Estimation of permanence time, exit time, dilution factor, and steady-state volume of distribution.

Authors:  J Mordenti; A Rescigno
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

4.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Mutational analysis of the cellular receptor for poliovirus.

Authors:  M S Freistadt; V R Racaniello
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

Review 6.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

7.  Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.

Authors:  C L Harris; A S Williams; S M Linton; B P Morgan
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.

Authors:  A Pinter; W J Honnen; S A Tilley
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120.

Authors:  R L Willey; M A Martin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.